Understand the source comparison
How to Use Survodutide for NASH Protocol: Comparison
Starting Dose 1.2mg 5–8% 10–15% Dose escalation phase only. Insufficient for hepatic endpoints Titration dose. Not therapeutic Low Maintenance 2.4mg 12–15% 15–20% Metabolic studies, short-duration steatosis models Effective for fat reduction without fibrosis a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Starting Dose
- 1.2mg
- 5–8%
- 10–15%
- Dose escalation phase only. Insufficient for hepatic endpoints
- Titration dose. Not therapeutic
- Low Maintenance
- 2.4mg
- 12–15%
- 15–20%
- Metabolic studies, short-duration steatosis models
- Effective for fat reduction without fibrosis assessment
- Standard Maintenance
- 3.6mg
- 20–25%
- Combined metabolic and histological endpoints
- Balanced efficacy and tolerability for most protocols
- High Maintenance
- 4.8mg
- 18–25%
- 25–30%
- Fibrosis reversal studies, long-duration NASH models
- Maximum efficacy. Requires GI management strategies
- Dose escalation must follow a structured timeline to maintain study integrity. Abrupt dose increases. Even at low absolute doses. Trigger receptor saturation that manifests as severe nausea, vomiting, and study dropout. The four-week step protocol exists because GLP-1 receptor downregulation in gastric tissue takes 21–28 days to complete. Researchers attempting to compress this timeline by increasing dose every two weeks consistently report higher adverse event rates without meaningful acceleration of therapeutic endpoints.